Royalty Pharma (RPRX) Q4 FY24 earnings call

Royalty Pharma delivered strong financial results in Q4 FY24, driven by robust portfolio performance and significant capital deployment into new royalties. The company is undergoing a transformative internalization of its external manager, expected to yield substantial long-term cash savings and strengthen shareholder alignment. Alongside a new $3 billion share repurchase authorization, these strategic moves aim to enhance shareholder value and position the company for continued compounding growth.